Medera

Executive Summary

Medera is a clinical-stage biopharmaceutical company pioneering novel gene- and cell-based therapies for cardiac, pulmonary, and vascular diseases. Founded in 2021 and headquartered in Cambridge, MA, the company leverages a proprietary intracoronary delivery method and a bioengineered human mini-Heart platform for preclinical screening. Its pipeline targets both common conditions like heart failure and rare diseases such as Duchenne muscular dystrophy-associated cardiomyopathy. By combining innovative delivery technology with a patient-specific screening model, Medera aims to address significant unmet needs in cardiovascular and muscular disorders. Despite being in the preclinical stage, the company's unique approach positions it as a potential leader in the field of gene and cell therapy for heart diseases.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Gene Therapy Program in Heart Failure60% success
• Q2 2026Preclinical Proof-of-Concept Data for DMD-Associated Cardiomyopathy70% success
• Q4 2026Strategic Partnership or Licensing Deal for Mini-Heart Platform40% success